Granuflo is a powder used in dialysis. Drug company Fresenius manufactures and distributes it.

Fresenius describes GranuFlo as “the most widely prescribed dry acid product” in the industry. It has a unique set of ingredients that dialysis patients convert into bicarbonate.

In regular use, many physicians and facilities prefer GranuFlo because it prevents injury to themselves and other workers. It keeps clinicians from having to use liquid acid, which can be very dangerous. It’s also lightweight and easy to transport. Its smaller size saves storage space.

However, studies have shown GranuFlo used in the last few years was not necessarily safe for the patients. Internal memos from Fresenius admit the concentrate had a higher amount of acetate and was raising patients’ risk of alkalosis. Severe health risks could follow, including heart attack, stroke, and death.

Cardiac disease is the leading cause of death for dialysis patients worldwide. It’s already a great risk to any patient on dialysis; but it’s potentially even more dangerous for someone who has used GranuFlo.

As one of the most widely distributed dialysis compounds in the world, GranuFlo has been administered to the majority of dialysis patients everywhere. Unfortunately, Fresenius chose not to make patients, or anyone outside of their clinics, aware of the added risks associated with their product.

Our law firm is accepting cases related to GranuFlo and dialysis injury. If you or a loved one received dialysis since 2009 and experienced a cardiac event, stroke, or death within a few days, you may be entitled to compensation.

Contact our Tennessee Fresenius attorneys for a free case evaluation.